Annual Accounts Payable
$14.59 M
+$4.79 M+48.92%
31 December 2023
Summary:
Vaxcyte annual accounts payable is currently $14.59 million, with the most recent change of +$4.79 million (+48.92%) on 31 December 2023. During the last 3 years, it has fallen by -$15.20 million (-51.03%). PCVX annual accounts payable is now -51.03% below its all-time high of $29.79 million, reached on 31 December 2020.PCVX Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Payable
$18.22 M
+$7.75 M+74.08%
30 September 2024
Summary:
Vaxcyte quarterly accounts payable is currently $18.22 million, with the most recent change of +$7.75 million (+74.08%) on 30 September 2024. Over the past year, it has increased by +$2.52 million (+16.02%). PCVX quarterly accounts payable is now -42.82% below its all-time high of $31.86 million, reached on 31 March 2021.PCVX Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PCVX Accounts Payable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +48.9% | +16.0% |
| 3 y3 years | -51.0% | -29.1% |
| 5 y5 years | +415.4% | - |
PCVX Accounts Payable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -51.0% | +115.8% | -29.1% | +279.5% |
| 5 y | 5 years | -51.0% | +415.4% | -42.8% | +612.8% |
| alltime | all time | -51.0% | +415.4% | -42.8% | +612.8% |
Vaxcyte Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $18.22 M(+74.1%) |
| June 2024 | - | $10.47 M(-51.8%) |
| Mar 2024 | - | $21.72 M(+48.9%) |
| Dec 2023 | $14.59 M(+48.9%) | $14.59 M(-7.1%) |
| Sept 2023 | - | $15.70 M(-3.5%) |
| June 2023 | - | $16.27 M(+40.0%) |
| Mar 2023 | - | $11.62 M(+18.6%) |
| Dec 2022 | $9.79 M | $9.79 M(+78.6%) |
| Sept 2022 | - | $5.49 M(-22.1%) |
| June 2022 | - | $7.04 M(+46.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2022 | - | $4.80 M(-29.0%) |
| Dec 2021 | $6.76 M(-77.3%) | $6.76 M(-73.7%) |
| Sept 2021 | - | $25.71 M(+8.5%) |
| June 2021 | - | $23.70 M(-25.6%) |
| Mar 2021 | - | $31.86 M(+7.0%) |
| Dec 2020 | $29.79 M(+782.3%) | $29.79 M(+178.8%) |
| Sept 2020 | - | $10.69 M(+318.0%) |
| June 2020 | - | $2.56 M(-3.5%) |
| Mar 2020 | - | $2.65 M(-21.5%) |
| Dec 2019 | $3.38 M(+19.3%) | $3.38 M |
| Dec 2018 | $2.83 M | - |
FAQ
- What is Vaxcyte annual accounts payable?
- What is the all time high annual accounts payable for Vaxcyte?
- What is Vaxcyte annual accounts payable year-on-year change?
- What is Vaxcyte quarterly accounts payable?
- What is the all time high quarterly accounts payable for Vaxcyte?
- What is Vaxcyte quarterly accounts payable year-on-year change?
What is Vaxcyte annual accounts payable?
The current annual accounts payable of PCVX is $14.59 M
What is the all time high annual accounts payable for Vaxcyte?
Vaxcyte all-time high annual accounts payable is $29.79 M
What is Vaxcyte annual accounts payable year-on-year change?
Over the past year, PCVX annual accounts payable has changed by +$4.79 M (+48.92%)
What is Vaxcyte quarterly accounts payable?
The current quarterly accounts payable of PCVX is $18.22 M
What is the all time high quarterly accounts payable for Vaxcyte?
Vaxcyte all-time high quarterly accounts payable is $31.86 M
What is Vaxcyte quarterly accounts payable year-on-year change?
Over the past year, PCVX quarterly accounts payable has changed by +$2.52 M (+16.02%)